This study, called PrEP4U, is looking at better ways to help people stick with HIV pre-exposure prophylaxis (PrEP) using an injectable medicine called lenacapavir. We want to see if giving you a choice in where you have your follow-up appointments (like at home or in the community, instead of always at the clinic) helps you continue using PrEP for longer. You can join if you are HIV-negative, eligible for PrEP, willing to receive lenacapavir injections, and live in Massachusetts. The main goal is to see how many people are still using PrEP at 6 months. We are currently unclear about the study's recruitment status, but it plans to enroll 400 people.

Study design

This is a randomized study, meaning participants will be assigned by chance to one of two groups, with 400 participants planned.

What's involved

You would receive injectable lenacapavir and follow study procedures, including follow-up appointments for 6 months.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for PrEP persistence at 6 months (26 weeks).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.